R. De Bock

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Lucien Noens, Marie-Anne van Lierde, R. De Bock et al. · Blood · 2009 · 615 citations · Full text

Medicine, Hematology, Oncology +7

Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy

Winfried V. Kern, Alain Cometta, R. De Bock et al. · New England Journal of Medicine · 1999 · 373 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL‐6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL‐6 levels and febrile transfusion reactions

L. Muylle, M. Joos, E. Wouters et al. · Transfusion · 1993 · 367 citations

Medicine, Hematology, Immunology +13

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program

Alain Cometta, Thierry Calandra, H. Gaya et al. · Antimicrobial Agents and Chemotherapy · 1996 · 275 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

Alain Cometta, Stephen H. Zinner, R. De Bock et al. · Antimicrobial Agents and Chemotherapy · 1995 · 247 citations

Pharmacy, Oncology, Pharmacotherapy +17